TY  - JOUR
AU  - Michel, Constance
AU  - Thibault, Constance
AU  - Oudard, Stephane
PY  - 2016
TI  - Long-term use of sunitinib in metastatic renal cell carcinoma: no unpleasant surprises about tolerability
JF  - Translational Cancer Research; Vol 5, Supplement 2 (August 22, 2016): Translational Cancer Research
Y2  - 2016
KW  - 
N2  - Metastatic relapse occurs in approximately 30% of patients who have previously undergone nephrectomy for renal cell carcinoma (1). Anti-angiogenic agents, such as tyrosine kinase inhibitors (TKI), have played a leading role in the treatment of metastatic renal cell carcinoma (mRCC) because it is highly resistant to chemotherapy. Sunitinib is a first-line TKI targeting both the vascular endothelial growth factor receptor (VEGFR) and the platelet-derived growth factor receptor (PDGFR). Treatment of mRCC with sunitinib has been shown to increase progression-free survival (PFS) to 11 months (95% confidence interval 0.32–0.54) versus 5 months with baseline interferon alpha treatment (P24 months’ therapy (2). This chronic use of sunitinib raises the question of long-term safety for patients treated for more than 2 years (3).
UR  - https://tcr.amegroups.org/article/view/8866